echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer

    Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer

    • Last Update: 2020-07-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Whether angiokine-strain conversion enzyme (ACE) inhibitors and angiotensin receptor blockers will alter the risk of colorectal cancer remains debatableIn a recent study published in the's authoritative journal of cardiovascular, researchers aimed to identify the link between taking these drugs after a baseline colonoscopy negative andthe risk of colorectal cancerthis is a regional retrospective cohort study that recruited patients over the age of 40 who underwent colonoscopies between 2005 and 2013Exclusion criteria include a colorectal examination within 6 monthsdiagnosedcolorectal cancer, past colorectal cancer, inflammatory bowel disease, and previous colonectomyThe main outcome of the study was the diagnosis of colorectal cancer between 6 and 36 months after a colonoscopyThe areas of colorectal cancer are divided into near-end cancer (near end to spleen) and distant cancerThe risk ratio for colorectal cancer, adjusted by ACE inhibitor/angiotensin receptor blockers, was derived by matching score regression on 23 covariates, including patient factors, simultaneous medication, and endoscopic center performanceof 187,897 eligible patients, 30856 (16.4%) of the subjects were given ACE inhibitors/angiotensin blockersBetween 6 and 36 months after a colonoscopy, 454 (0.45%) of the subjects developed colorectal cancer (near-end cancer: 147 people .17.2%)These drugs were associated with a lower risk of developing colorectal cancer less than 3 years after a colonoscopy (adjusted risk ratio was 0.78 (95% CI is 0.64-0.96), but not for colorectal cancer for more than 3 years (adjusted risk ratio was 1.18 (95% CI 0.88-1.57));so that ACE inhibitors/angiotensin receptor blockers reduce the risk of colorectal cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.